GlassScriptPhysician profile
Joseph E Hartig
NPI 1174583447
$1,958.97
in general payments reported to CMS, 2019-2025
25 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $227 · 2021: $364 · 2022: $359 · 2023: $296 · 2024: $261 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $723.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $707.31 | 2021-2025 | |
| Glaxosmithkline, LLC. | $259.79 | 2019-2022 | |
| Novo Nordisk INC | $165.56 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $139.81 | 2019-2022 | |
| Abbott Laboratories | $110.39 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $65.75 | 2020 | |
| Allergan, INC. | $58.02 | 2019-2020 | |
| Lilly USA, LLC | $54.96 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $53.49 | 2020-2025 | Repatha, Otezla |
| Pfizer INC. | $51.05 | 2020-2021 | |
| Cranial Technologies, INC | $32.92 | 2021-2023 | Doc Band |
| Astellas Pharma US INC | $29.69 | 2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $28.90 | 2019 | |
| Supernus Pharmaceuticals, INC. | $28.86 | 2021-2024 | Qelbree |
| Esperion Therapeutics, INC. | $25.53 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $24.18 | 2019 | |
| Inspire Medical Systems, INC. | $20.41 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $16.38 | 2025 | Voquezna |
| Exact Sciences Corporation | $15.60 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $13.21 | 2019 | |
| Daiichi Sankyo INC. | $11.65 | 2019 | |
| Ethicon US, LLC | $11.51 | 2019 | |
| Genentech USA, INC. | $11.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.40 | 2021 | |
| Vanda Pharmaceuticals INC. | $11.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Hartig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.